333 related articles for article (PubMed ID: 19414747)
1. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.
Hong Y; Peng Y; Xiao H; Mi M; Munn D; He Y
J Immunol; 2012 May; 188(10):4819-27. PubMed ID: 22504640
[TBL] [Abstract][Full Text] [Related]
3. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
4. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector.
Colombetti S; Lévy F; Chapatte L
Blood; 2009 Jun; 113(26):6629-37. PubMed ID: 19383968
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.
Lopes L; Dewannieux M; Gileadi U; Bailey R; Ikeda Y; Whittaker C; Collin MP; Cerundolo V; Tomihari M; Ariizumi K; Collins MK
J Virol; 2008 Jan; 82(1):86-95. PubMed ID: 17959670
[TBL] [Abstract][Full Text] [Related]
6. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
[TBL] [Abstract][Full Text] [Related]
7. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
8. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.
Zhou Q; Xiao H; Liu Y; Peng Y; Hong Y; Yagita H; Chandler P; Munn DH; Mellor A; Fu N; He Y
J Immunol; 2010 Nov; 185(9):5082-92. PubMed ID: 20926790
[TBL] [Abstract][Full Text] [Related]
9. An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.
Rausch MP; Hastings KT
PLoS One; 2015; 10(4):e0123332. PubMed ID: 25875653
[TBL] [Abstract][Full Text] [Related]
10. CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.
Pavelko KD; Hansen MJ; Pease LR
Cancer Res; 2009 Apr; 69(7):3114-20. PubMed ID: 19276379
[TBL] [Abstract][Full Text] [Related]
11. Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.
Xiao H; Peng Y; Hong Y; Liu Y; Guo ZS; Bartlett DL; Fu N; He Y
J Immunol; 2011 Aug; 187(4):1788-96. PubMed ID: 21746967
[TBL] [Abstract][Full Text] [Related]
12. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
14. Immune rejection of mouse tumors expressing mutated self.
Duan F; Lin Y; Liu C; Engelhorn ME; Cohen AD; Curran M; Sakaguchi S; Merghoub T; Terzulli S; Wolchok JD; Houghton AN
Cancer Res; 2009 Apr; 69(8):3545-53. PubMed ID: 19351857
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
17. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
[TBL] [Abstract][Full Text] [Related]
18. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
19. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
20. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.
Sierro SR; Donda A; Perret R; Guillaume P; Yagita H; Levy F; Romero P
Eur J Immunol; 2011 Aug; 41(8):2217-28. PubMed ID: 21538347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
